{"id":"clofoctol","rwe":[{"pmid":"41430270","year":"2025","title":"Activation of the cGAS-STING pathway by clofoctol through mitochondrial damage in triple-negative breast cancer.","finding":"","journal":"Journal of translational medicine","studyType":"Clinical Study"},{"pmid":"40492418","year":"2025","title":"A Novel Class of Multi-substituted Diaryl Scaffold Derivatives Inhibit Glioblastoma Progression by Targeting CD155.","finding":"","journal":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","studyType":"Clinical Study"},{"pmid":"40325218","year":"2025","title":"Clofoctol impairs the stemness of gastric cancer and induces TNF-mediated necroptosis by directly binding to RanBP2.","finding":"","journal":"Cellular and molecular life sciences : CMLS","studyType":"Clinical Study"},{"pmid":"40280285","year":"2025","title":"Pulmonary delivery of clofoctol-loaded nanoparticles inhibits SARS-CoV-2 replication and reduces pneumonia.","finding":"","journal":"International journal of pharmaceutics","studyType":"Clinical Study"},{"pmid":"38973459","year":"2024","title":"KLF13 restrains Dll4-muscular Notch2 axis to improve the muscle atrophy.","finding":"","journal":"Journal of cachexia, sarcopenia and muscle","studyType":"Clinical Study"}],"tags":[{"label":"clofoctol","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"J01XX03","category":"atc"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"octofene","offLabel":[],"synonyms":["clofoctol","octofene"],"timeline":[],"approvals":[],"brandName":"Octofene","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"clofoctol","explanation":"Imagine your body's cells have locks on them, and Octofene has a key that fits into those locks. When it binds to the lock, it triggers a response that helps to treat a particular condition. This is a simplified explanation of how Octofene works at a molecular level.","oneSentence":"Octofene works by interacting with a specific target to produce its therapeutic effect.","technicalDetail":"Octofene is a small molecule that binds to a specific target, likely a receptor or enzyme, to produce its therapeutic effect. The exact mechanism of action is not specified, but it is believed to involve modulation of a biological pathway to produce a desired outcome."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3109","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CLOFOCTOL","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:10:52.402029","biosimilars":[],"competitors":[{"drugName":"fosfomycin","drugSlug":"fosfomycin","fdaApproval":"1996-12-19","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"spectinomycin","drugSlug":"spectinomycin","fdaApproval":"1971-06-30","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"methenamine","drugSlug":"methenamine","fdaApproval":"1967-07-05","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"linezolid","drugSlug":"linezolid","fdaApproval":"2000-04-18","genericCount":24,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"daptomycin","drugSlug":"daptomycin","fdaApproval":"2003-09-12","patentExpiry":"Sep 4, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"bacitracin","drugSlug":"bacitracin","fdaApproval":"1948-07-29","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"tedizolid phosphate","drugSlug":"tedizolid-phosphate","fdaApproval":"2014-06-20","patentExpiry":"Jun 20, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"lefamulin","drugSlug":"lefamulin","fdaApproval":"2019-08-19","patentExpiry":"May 23, 2031","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"clofoctol","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"fosfomycin","brandName":"fosfomycin","genericName":"fosfomycin","approvalYear":"1996","relationship":"same-class"},{"drugId":"spectinomycin","brandName":"spectinomycin","genericName":"spectinomycin","approvalYear":"1971","relationship":"same-class"},{"drugId":"methenamine","brandName":"methenamine","genericName":"methenamine","approvalYear":"1967","relationship":"same-class"},{"drugId":"linezolid","brandName":"linezolid","genericName":"linezolid","approvalYear":"2000","relationship":"same-class"},{"drugId":"daptomycin","brandName":"daptomycin","genericName":"daptomycin","approvalYear":"2003","relationship":"same-class"},{"drugId":"bacitracin","brandName":"bacitracin","genericName":"bacitracin","approvalYear":"1948","relationship":"same-class"},{"drugId":"tedizolid-phosphate","brandName":"tedizolid phosphate","genericName":"tedizolid phosphate","approvalYear":"2014","relationship":"same-class"},{"drugId":"lefamulin","brandName":"lefamulin","genericName":"lefamulin","approvalYear":"2019","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"005509","UNII":"704083NI0R","CHEBI":"CHEBI:108581","INN_ID":"4126","RXNORM":"21264","UMLSCUI":"C0055915","ChEMBL_ID":"CHEMBL1476605","KEGG_DRUG":"D07244","DRUGBANK_ID":"DB13237","PUBCHEM_CID":"2799","MESH_SUPPLEMENTAL_RECORD_UI":"C018874"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":41,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"J01XX03","allCodes":["J01XX03"]},"biosimilarFilings":[],"recentPublications":[{"date":"2025 Dec 22","pmid":"41430270","title":"Activation of the cGAS-STING pathway by clofoctol through mitochondrial damage in triple-negative breast cancer.","journal":"Journal of translational medicine"},{"date":"2025 Aug","pmid":"40492418","title":"A Novel Class of Multi-substituted Diaryl Scaffold Derivatives Inhibit Glioblastoma Progression by Targeting CD155.","journal":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)"},{"date":"2025 May 6","pmid":"40325218","title":"Clofoctol impairs the stemness of gastric cancer and induces TNF-mediated necroptosis by directly binding to RanBP2.","journal":"Cellular and molecular life sciences : CMLS"},{"date":"2025 May 30","pmid":"40280285","title":"Pulmonary delivery of clofoctol-loaded nanoparticles inhibits SARS-CoV-2 replication and reduces pneumonia.","journal":"International journal of pharmaceutics"},{"date":"2024 Oct","pmid":"38973459","title":"KLF13 restrains Dll4-muscular Notch2 axis to improve the muscle atrophy.","journal":"Journal of cachexia, sarcopenia and muscle"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Octofene, also known as CLOFOCTOL, is a small molecule drug in the clofoctol class. It is currently owned by an unknown entity, and its target and exact mechanism of action are not specified. Octofene is not FDA-approved, and its commercial status, including patent and generic availability, is unknown. As a result, there is limited information available on its approved indications, half-life, bioavailability, and key safety considerations. Further research is needed to fully understand the properties and uses of Octofene.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}